AIDS Research and Treatment / 2015 / Article / Tab 4

Research Article

Efficacy of Once Daily Darunavir/Ritonavir in PI-Naïve, NNRTI-Experienced Patients in the ODIN Trial

Table 4

HIV-1 RNA suppression at week 48, by number of active NRTIs and baseline CD4 count.

Darunavir/ritonavir
800/100 mg once daily
Darunavir/ritonavir
600/100 mg twice daily

HIV-1 RNA <50 copies/mL
 Number of active NRTIs
  06/7 (86%)8/9 (89%)
  130/34 (88%)32/35 (91%)
  ≥264/85 (75%)69/88 (78%)

HIV-1 RNA <400 copies/mL
 Number of active NRTIs
  06/7 (86%)9/9 (100%)
  131/34 (91%)32/35 (91%)
  ≥264/85 (75%)74/88 (84%)

HIV-1 RNA <50 copies/mL
 Baseline CD4 count
  <200 cells/µL49/59 (83%)41/54 (76%)
  ≥200 cells/µL62/76 (82%)68/83 (82%)

HIV-1 RNA <400 copies/mL
 Baseline CD4 count
  <200 cells/µL51/59 (86%)44/54 (82%)
  ≥200 cells/µL67/76 (88%)71/83 (86%)

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.